A Study Investigating agenT-797 in Participants With Relapsed/Refractory Solid Tumors

Inclusion Criteria:

Histological or cytological evidence of relapsed or refractory solid tumor malignancy for which no standard therapy is available or standard therapy has failed
Measurable disease per RECIST 1.1 as assessed by local site Investigator/radiology. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions
Part 2 only, participants must have progressed per Investigator assessment on pembrolizumab or nivolumab, and agree and are able to continue on the inhibitor(s) while on study
No other medical, surgical, or psychiatric condition (including active substance abuse) that would interfere with compliance to the protocol, as determined by the Principal Investigator

Exclusion Criteria:

Concurrent invasive malignancy
Brain and/or leptomeningeal metastases that are untreated or require current therapy
Prior radiotherapy within 2 weeks of start of study treatment